Company: SCLXW
Filing Date: 2025-05-16
Form Type: DEF 14A
Source: 0000950170-25-073612
Chunk: 83

Company: Scilex Holding Co
Filing Date: 2025-05-16
Form: DEF 14A
Chunk 83
---
Gloperba-ElyxybRoyalty Security Agreement, we entered into that certainGloperba and ElyxybSubordination Agreement, dated as of February 28, 2025 (the “Gloperba-ElyxybSubordination Agreement”), by and among us, Scilex Pharma the Gloperba-Elyxyb RPA Purchasers and the Note Agent (each as defined in theGloperba-ElyxybSubordination Agreement). Pursuant to theGloperba-ElyxybSubordination Agreement, the parties agreed that all obligations, liabilities and indebtedness under theGloperba-ElyxybRoyalty Purchase Agreement are secured by first priority liens on the collateral under theGloperba-ElyxybRoyalty Security Agreement (the “Gloperba-ElyxybRoyalty Collateral”) and the Note Agent’s lien on theGloperba-ElyxybRoyalty Collateral is subordinated and becomes a second priority lien.

The foregoing summaries of the Gloperba-ElyxybRoyalty Purchase Agreement, theGloperba-ElyxybRoyalty Security Agreementand the Gloperba-ElyxybSubordination Agreementdo not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, a copy of each of which is filed as an exhibit to our Current Report on Form 8-K filed on March 3, 2025.

Gloperba Rest of World License Agreement

On February 28, 2025 (the “Effective Date”), we entered into a License Agreement (the “Gloperba License Agreement”) with Scilex Pharma and the Licensee with respect to (i) services, compositions, products, dosages and formulations comprising Gloperba that have been or are later developed by or on behalf of us, including the product and any future product defined as a “Licensed Product” under the License and Commercialization Agreement, dated as of June 14, 2022, by and between RxOmeg Therapeutics LLC (“Romeg”) and us, as amended by that certain First Amendment to License and Commercialization Agreement, dated January 16, 2025, by and between Romeg and us, as may be further amended or restated from time to time, and (ii) any related, improved, successor or replacement forms of any such product Controlled (as defined therein) by us ((i) and (